Feasibility of a Cell Kinetic-Based Adjuvant Chemotherapy Trial in Axillary Node-Negative Breast Cancer

Adami H.O. , Graffman S. , Lindgren A. , Sallstrom J. : Prognostic implications of estrogen receptor content in breast cancer. Breast Cancer Res. Treat., 5: 293–300, 1985.

Amadori D. , Volpi A. , Callea A. : Clinical relevance of cell kinetics in breast cancer. Ann. N. Y. Acad. Sci., 698: 186–192, 1994.

Amadori D. , Volpi A. , Maltoni R. , Nanni O. , Amaducci L. , Amadori A. , Casadei Giunchi D. , Vio A. , Saragoni A. , Silvestrini R. : Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res. Treat., 43: 7–14, 1997.

Bonetti A. , Zaninelli M. , Rodella S. , Molino A. , Sperotto L. , Piubello Q. , Bonetti F. , Nortilli R. , Turazza M. , Cetto G.L. : Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res. Treat., 38: 289–297, 1996.

Catzavelos C. , Bhattacharya N. , Ung Y.C. , Wilson J.A. , Roncari L. , Sandhu C. , Shaw P. , Yeger H. , Morava-Protzner I. , Kapusta L. , Franssen E. , Pritchard K.I. , Slingerland J.M. : Decreased levels of the cell-cycle inhibitor p27kip 1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227–230, 1997.

Clark G.M. , Dressier L.G. , Owens MA. , Pounds G. , Oldaker T. , McGuire W.L. : Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. NEJM, 320: 627–633, 1989.

Clinical Alert from the National Cancer Institute. Breast Cancer Res. Treat., 12: 3–5, 1988.

Contesso G. , Mouresse H. , Friedman S. , Genin J. , Sarrazin D. , Rouesse J. : The importance of histologic grade in long-term prognosis of breast cancer. A study of 1010 patients, uniformly treated in the Institute Gustave Roussy. J. Clin. Oncol., 5: 1378–1386, 1987.

Di Fronzo G. , Coradini D. , Cappelletti V. , Miodini P. , Granata G. , Schwartz M. , Panko W.B. : Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Anticancer Res., 10: 1690–1706, 1990.

Fisher B. , Costantino J. , Redmond C. , Poisson R. , Bowman D. , Couture J. , Dimitrov N.V. , Wolmark N. , Wickerham D.L. , Fisher E.R. , Margolese R. , Robidoux A. , Shibata H. , Terz J. , Paterson A.H.G. , Feldman M.I. , Farrar W. , Evans J. , Lickley H.L. , Ketner M. : A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. NEJM, 320: 479–484, 1989.

Fisher B. , Fisher E.R. , Redmond C. , Brown A. : Tumor nuclear grade, estrogen and progesterone receptors: their value alone or in combinations as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res. Treat., 7: 147–160, 1986.

Fisher B. , Redmond C. , Dimitrov N.V. , Bowman D. , Legault-Poisson S. , Wickerham D.L. , Wolmark N. , Fisher E.R. , Margolese R. , Sutherland C. , Glass A. , Foster R. , Caplan R. : A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. NEJM, 320: 473–478, 1989.

Fisher B. , Slarck N. , Katrych D. , Wolmark N. : Ten-year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg. Gynecol. Obstet., 140: 528–534, 1975.

Gentili C. , Sanfilippo O. , Silvestrini R. : Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer, 48: 974–979, 1981.

Hedley D.W. , Rugg C.A. , Ng A.B. , Taylor I.W. : Influence of cellular DNA content on disease free survival of stage II breast cancer patients. Cancer Res., 44: 5395–5398, 1984.

Hery M. , Gioanni C.M. , Lalanne C.M. , Namei M. , Courdi A. : The DNA labeling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res. Treat., 9: 207–212, 1987.

Knight W.A. , Livingstone R.B. , Gregory E.J. , McGuire W.L. : Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res., 37: 4669–4671, 1977.

Mansour E.G. , Gray R. , Shatila A.M. , Osborne C.K. , Tormey D.C. , Gilchrist K.W. , Cooper M.R. , Falkson G. : Efficacy of adjuvant chemotherapy in high risk node negative breast cancer. NEJM, 320: 1989, 485–490, 1989.

Meyer J.S. , Friedman E. , McCrate M.M. , Bauer W.C. : Prediction of early course of breast carcinoma by thymidine labeling. Cancer, 51: 1879–1886, 1983.

Meyer J.S. , Lee J.Y. : Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness and duration of survival. Cancer Res., 40: 1890–1896, 1980.

Meyer J.S. : Proliferation assay in prognosis of cancer. J. Clin. Immunoassay, 14: 164–170, 1991.

Meyer J.S. , Province M. : Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res. Treat., 12: 191–204, 1988.

Novaldex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years. Br. J. Cancer, 57: 608–611, 1988.

Paradiso A. , Lorusso V. , Tommasi S. , Schittulli F. , Maiello E. , De Lena M. : Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer. Breast Cancer Res. Treat., 11: 31–36, 1988.

Paradiso A. , Mangia A. , Barletta A. , Catino A.M. , Giannuzzi A. , Schittulli F. , Radogna N. , Longo S. , Palmieri D. , Marzullo F. , Natale C. , Tardio B. , De Lena M. : Randomized clinical trial of adjuvant chemotherapy in patients with node-negative fast proliferating breast cancer. Drugs, 45(Suppl. 2): 68–74, 1993.

Paradiso A. , Tommasi S. , Mangia A. , Lorusso V. , Simone G. , De Lena M. : Tumor-proliferative activity, progesterone receptor status, estrogen receptor level and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res., 50: 2958–2962, 1990.

Pestalozzi B.C. , Peterson H.F. , Gelber R.D. , Goldhirsch A. , Gusterson B.A. , Trihia H. , Lindtner J. , Cortes-Fines H. , Simmoncini E. , Byrne M.J. , Golouh R. , Rudenstam C.M. , Castiglione-Gertsch M. , Allegra C.J. , Johnston P.G. : Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol., 15: 1923–1931, 1997.

Piffanelli A. , Pelizzola D. , Giovannini G. , Catozzi L. , Faggioli L. , Giganti M. : Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation of breast cancer biopsies. Tumori, 75: 550–556, 1989.

Porter P.L. , Malone K.E. , Heagerty P.J. , Alexander G.M. , Gatti L.A. , Firpo E.J. , Daling J.R. , Roberts J.M. : Expression of cell-cycle regulators p27Kip 1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222–225, 1997.

Remvikos Y. , Beuzeboc P. , Zajdela A. , Voillemot N. , Magdelenat H. , Pouillart P. : Correlation of pretreatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J. Natl. Cancer Inst., 81: 1383–7, 1989.

Silvestrini R. and the SICCAB group for quality control of cell kinetic determination. Feasibility and reproducibility of the 3H-TdR labeling index in breast cancer. Cell Prolif., 21: 437–445, 1991.

Silvestrini R. , Benini E. , Daidone M.G. , Veneroni S. , Boracchi P. , Cappelletti V. , Di Fronzo G. , Veronesi U. : p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 965–970, 1993.

Silvestrini R. , Daidone M.G. , Benini E. , Faranda A. , Tomasic G. , Boracchi P. , Salvadori B. , Veronesi U. : Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin. Cancer Res., 2: 2007–2013, 1996.

Silvestrini R. , Daidone M.G. , Costa A. : Cell kinetics of solid tumors with time and its clinical implications. Tumori, 75: 367–372, 1989.

Silvestrini R. , Daidone M.G. , Del Bino G. , Mastore M. , Di Fronzo G. , Boracchi P. : Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann. Oncol., 4: 13–219, 1993.

Silvestrini R. , Daidone M.G. , Di Fronzo G. , Morabito A. , Valagussa P. , Bonadonna G. : Prognostic implications of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res. Treat., 7: 161–169, 1986.

Silvestrini R. , Daidone M.G. , Luisi A. , Boracchi P. , Mezzetti M. , Di Fronzo G. , Andreola S. , Veronesi U. : Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol, 13: 697–704, 1995.

Silvestrini R. , Daidone M.G. , Valagussa P. : Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat. Rep., 4: 375–379, 1987.

Silvestrini R. , Daidone M.G. , Valagussa P. , Di Fronzo G. , Mezzanotte G. , Bonadonna G. : Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur. J. Cancer Clin. Oncol., 25: 1165–1171, 1989.

Silvestrini R. , Daidone M.G. , Valagussa P. , Di Fronzo G. , Mezzanotte G. , Mariani L. , Bonadonna G. : 3H-Thymidine labeling index as a prognostic indicator in node-positive breast cancer. J. Clin. Oncol., 8: 1321–1326, 1990.

Silvestrini R. , Veneroni S. , Daidone M.G. , Benini E. , Boracchi P. , Mezzetti M. , Di Fronzo G. , Veronesi U. : The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499–504, 1994.

Skipper H.E. : Kinetic behavior versus response to chemotherapy. N.C.I. Monogr., 34: 2–14, 1971.

Stal O. , Skoog L. , Rutqvist L.E. , Carstensen J.M. , Wingren S. , Sullivan S. , Andersson A.C. , Dufmats M. , Nordenskjold B. : S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br. J. Cancer, 70: 1258–1262, 1994.

Sulkes A. , Livingstone R.B. , Murphy W.K. : Tritiated thymidine labeling index and response in human breast cancer. J. Natl. Cancer Inst., 62: 513–515, 1979.

Tan P. , Cady B. , Wanner M. , Worland P. , Cukor B. , Magi-Galluzzi C. , Lavin P. , Draetta G. , Pagano M. , Loda M. : The cell-cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinoma. Cancer Res., 57: 1259–1263, 1997.

Toikkanen S. , Helin H. , Isola J. , Joensuu H. : Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J. Clin. Oncol., 10: 1044–1048, 1992.

Tubiana M. , Courdi A. : Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother. Oncol., 15: 1–18, 1989.

Tubiana M. , Pejovic M.H. , Chavaudra N. , Malaise E.P. : The long term prognostic significance of thymidine labelling index in breast cancer. Int. J. Cancer, 33: 441–445, 1984.

Tubiana M. , Pejovic M.H. , Koscielny S. , Chavaudra N. , Malaise E. : Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int. J. Cancer, 44: 17–22, 1989.

Valagussa P. , Bonadonna G. , Veronesi U. : Patterns of relapse and survival following radical mastectomy. Cancer, 41: 1170–1178, 1978.

Wenger C.R. , Beardslee S. , Owens M.A. , Pounds G. , Oldaker T. , Vendely P. , Pandian M.R. , Harringon D. , Clark G.M. , McGuire W.L. : DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res. Treat., 28: 9–20, 1993.

Zambetti M. , Bonadonna G. , Valagussa P. , Daidone M.G. , Coradini D. , Bignami P. , Contesso G. , Silvestrini R. : Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. J. Natl. Cancer Inst. Monogr., 11: 77–83, 1992.

Zambetti M. , Valagussa P. , Bonadonna G. : Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Ann. Oncol., 7: 481–485, 1996.